Health

Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy

The study confirms that Xanamem is a brain-penetrant inhibitor of the tissue cortisol synthesis enzyme, 11β-HSD1, with high levels of target occupancy at doses as low as 5 mg SYDNEY, Jan. 24, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that its human Positron Emission Tom...

2024-01-24 21:30 1640

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio® for the Treatment of Gastric Cancer Poster presented at ASCO GI

* Results showed partial response being confirmed in 7 out of 42 patients * Partial response was observed in 3 out of 8 patients who were previously treated by immunotherapy SEOUL, South Korea, Jan. 24, 2024 /PRNewswire/ -- Genome & Company (KOSDAQ: 314130), a clinical stage biotech leading in...

2024-01-24 21:00 1635

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

Eli Lilly and Company, Santec Holdings Corporation participated in the round TOKYO, Jan. 24, 2024 /PRNewswire/ -- TOKYO, Jan. 24, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protei...

2024-01-24 16:00 1474

Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 23, 2024 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142) announced that the Company has been granted the clearance of Investigational New Drug (IND) from the Food and Drug Administration (FDA) ofthe United States to init...

2024-01-24 12:40 1653

WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs)

SHANGHAI and INCHEON, South Korea, Jan. 23, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltrion, Inc. (068270.KS), a leading global biopharmaceutical...

2024-01-24 11:37 1463

PharmAbcine Announces First Patient Dosed in Phase 1a/b Clinical Trial of PMC-309 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Solid Tumors

* Initiation of Phase 1a/b clinical trial exploring MTD, RP2D, safety and tolerability of PMC-309 monotherapy and combination therapy with KEYTRUDA® * The clinical trial aims to enroll a total of 67 patients across four institutions inAustralia DAEJEON, South Korea, Jan. 23, 2024 /PRNewswire/ ...

2024-01-24 10:01 1297

Datasea Pre-Announces First Half 2024 Revenue of $18.2 Million, a 1,037.5% Year-Over-Year Increase

BEIJING, Jan. 23, 2024 /PRNewswire/ -- Datasea Inc., (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada incorporated digital technology corporation engaged in converging and innovative business segments for intelligent acoustics and 5G messaging technology inChina pre-announced that its revenue...

2024-01-23 22:35 3285

Rhino Rescue Speeds into the Future of First-Aid Supplies with New Year Resolutions for 2024

Propelling Lifesaving Measures with User-friendly Innovations in 2024 SHANGHAI, Jan. 23, 2024 /PRNewswire/ -- As the New Year unfolds, Rhino Rescue , a global innovator in premier first-aid supplies, would like to take a moment to reflect upon and celebrate its rem...

2024-01-23 22:15 1753

Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

HONG KONG, Jan. 23, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso," "we," or the "Company") today announced that the Company presented the promising phase II results of cadonilimab (a tetravalent PD-1/CTLA-4 bispecific antibody) and Lenvatinib (Len) combined with TACE for the treatment of mi...

2024-01-23 21:00 3218

Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction

NEW TAIPEI CITY, Jan. 23, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announces that Australian Bellberry HREC has approved Caliway's application to initiate CBL-514's Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction. "We are all delighted to see CBL-514 show...

2024-01-23 18:35 1306

Baird Medical Performs First Thyroid Microwave Ablation Procedure in the United States

FRISCO, Texas, Jan. 23, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced that it has performed its first thyroid MWA procedure inthe United...

2024-01-23 18:00 1314

European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)

YONGIN, South Korea, Jan. 22, 2024 /PRNewswire/ -- GC Biopharma Corp. (006280.KS) announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its intracerebroventricular (ICV) Enzyme Replacement Therapy (ERT) candidate, GC1130A, designed for Sanfilippo Syndrome...

2024-01-23 11:53 1510

36,000 units of MAIDeSITe Electric Floor Lift have been sold on Amazon

HANGZHOU, China, Jan. 22, 2024 /PRNewswire/ -- The MAIDeSITe Electric Floor Lift is a secure and independent mobility aid. Beyond being FDA-certified, it has consistently been a best seller onAmazon . Currently,...

2024-01-23 10:59 1188

UHS deploys Cutting-Edge Robotic Cleaning Technology developed by CenoBots

AUSTIN, Texas, Jan. 22, 2024 /PRNewswire/ -- CenoBots is excited to announce its partnership with UHS fromSan Antonio, a valued hospital system partner, for deploying cleaning robots. The deployment is also being carried out in collaboration with Hellogard Robotics. This collaboration serves as a...

2024-01-22 21:00 1238

NK CellTech Announces FDA Clearance for Clinical Trial of NK010

SHANGHAI, Jan. 22, 2024 /PRNewswire/ -- On January 17, 2024, NK CellTech Co., Ltd. (NK CellTech), a leading biotech company focused on the development of NK cellular therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of NK010, the non-genetically modified ...

2024-01-22 20:10 1472

Sanyou Super Trillion Peptide Molecule Discovery Platform Officially Launched Today

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- On January 13, 2024 local time, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. officially announced the launch of its "Sanyou Super Trillion Peptide Molecule Discovery Platform". The Sanyou Super Trillion Peptide Molecule Discovery Platform is an integral ...

2024-01-20 08:00 2568

Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI

BEIJING and SAN FRANCISCO, Jan. 19, 2024 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients with pancreatic cancer and other solid tumors in the oral abstract session at the American Socie...

2024-01-20 06:30 2697

Datasea Enters into Agreement with U.S. Marketing Firm to Promote and Market its Innovative Intelligent Acoustics Products

The Agreement is Expected to Expand DTSS' Footprint in the U.S. and Increase Product Sales BEIJING, Jan. 19, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), which engages in the business segments of U.S.-based intelligent acoustics andChina-based 5G messaging techn...

2024-01-19 22:00 1971

CARsgen's Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

SHANGHAI, Jan. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2024 American Society of Clinical Oncology Gastrointestin...

2024-01-19 21:50 1902

Harbour BioMed Announces Positive Profit Alert

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 18, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2024-01-19 12:52 5443
1 ... 50515253545556 ... 280